Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Gain Therapeutics ( (GANX) ) has issued an update.
Gain Therapeutics has appointed Gene Mack as its new Chief Executive Officer and Director, effective January 6, 2025. Mack, previously the CFO and interim CEO, will lead the company as it progresses its lead candidate GT-02287 through clinical trials for Parkinson’s disease. Gianluca Fuggetta will take on the role of Senior Vice President, Finance. The appointments are expected to maintain leadership continuity and support the company’s strategic objectives. GT-02287, Gain’s lead drug candidate, is undergoing Phase 1b clinical trials and has shown promising preclinical results in treating Parkinson’s disease. Supported by organizations like The Michael J. Fox Foundation, the drug demonstrates potential to slow or stop disease progression.
More about Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric small molecule therapies. The company is advancing its lead drug candidate, GT-02287, for the treatment of Parkinson’s disease, utilizing its proprietary Magellan™ platform to target neurodegenerative diseases, rare genetic disorders, and oncology.
YTD Price Performance: 5.17%
Average Trading Volume: 300,151
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $64.72M
Learn more about GANX stock on TipRanks’ Stock Analysis page.
